ELLON (Bach U.S.A.) Inc. – Trademark Portfolio
Entity Type: 03
ELLON (Bach U.S.A.) Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include BACH FLOWER REMEDIES. The owner is based in Woodmere, NY.
457 Rockaway Ave.
Woodmere, NY 11598
Showing of trademarks Trademarks
Trademark Classifications
ELLON (Bach U.S.A.) Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Education; providing of training; entertainment; sporting and cultural activities
Beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages
Frequently Asked Questions
How many trademarks does ELLON (Bach U.S.A.) Inc. have?
ELLON (Bach U.S.A.) Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 3 cancelled.
What trademark classes does ELLON (Bach U.S.A.) Inc. file in?
ELLON (Bach U.S.A.) Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 32 (Light Beverages). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are ELLON (Bach U.S.A.) Inc.'s most well-known trademarks?
ELLON (Bach U.S.A.) Inc.'s registered trademark portfolio includes well-known marks such as BACH FLOWER REMEDIES. These are among 1 currently registered trademark in the portfolio.
What is ELLON (Bach U.S.A.) Inc.'s trademark registration success rate?
ELLON (Bach U.S.A.) Inc. has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.